NEW YORK, March 12, 2021 /PRNewswire/ -- AIkido Pharma Inc.
(Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr.
Matt Frieman appeared on the video
podcast This Week in Virology, segment entitled "TWiV 729: A floret
of spikes with Matt Frieman."
In the video, Dr. Frieman discusses the Covid-19 pandemic from
the point of view of a coronavirologist.
The entire video can be seen here:
At the forty-two minute mark, Dr. Frieman discusses the future
of this type of virology work and his work on the pan-viral
initiative with AIkido Pharma. The Company is proud to be
working with industry leaders like Dr. Frieman in the development
of a family of pan-viral drugs.
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology company with a
diverse portfolio of small-molecule anti-cancer therapeutics.
The Company's platform consists of patented technology from leading
universities and researchers and we are currently in the process of
developing an innovative therapeutic drug platform through strong
partnerships with world renowned educational institutions,
including The University of Texas at Austin and Wake Forest
University. Our diverse pipeline of therapeutics includes therapies
for pancreatic cancer, acute myeloid leukemia (AML) and acute
lymphoblastic leukemia (ALL). In addition, we are constantly
seeking to grow our pipeline to treat unmet medical needs in
oncology. The Company is also developing a broad-spectrum
antiviral platform that may potentially inhibit replication of
multiple viruses including Influenza virus, SARS-CoV (coronavirus),
MERS-CoV, Ebolavirus and Marburg virus.
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the SEC,
not limited to Risk Factors relating to its business contained
therein. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Brett Maas, Managing Partner
Phone: (646) 536-7331
AIkido Pharma Inc.:
View original content to download
SOURCE AIkido Pharma Inc.